In November 2021, we were pleased to announce our investment in Kiniciti, a Cell & Gene Therapy (“CGT”) aggregator. Later in November, Kiniciti announced its first strategic partnership with Ncardia, a leader in developing stem cell-based solutions for drug discovery and cell therapy. Kiniciti’s partnership and investment will allow Ncardia to build GMP capabilities to support iPSC cell therapy platforms and human cell-based in vitro discovery services.

We recently hosted a discussion with Geoffrey Glass, Kiniciti’s CEO. In the video below, Geoff discusses:

The future of Cell and Gene Therapy
Allogeneic vs Autologous therapies
Ncardia and IPSCs (Induced pluripotent stem cells)
The vision for Kiniciti’s platform and ecosystem

Connect with Kiniciti:

Career opportunities at Ncardia: